New Treatment Guidelines for Unstable Angina/Non—ST-Segment Elevation Myocardial Infarction

Braunwald E Antman EM Beasley JW Califf RM Cheitlin MD Hochman JS ACC/AHA 2002 guideline update for the management of patients with unstable angina and non—ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). 2002 [cited 2002 Oct 1]. Available from: URL:http://www.acc.org/clinical/guidelines/unstable/unstable.pdf.

Bertrand ME Rupprecht HJ Urban P Gershlick AH Investigators FT . Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting. Circulation 2000;102: 624–9.

Bennett CL Connors JM Carwile JM Moake JL Bell WR Tarantolo SR Thrombotic thrombocytopenia purpura associated with clopidogrel. N Engl J Med 2000;342: 1773–7.

Bennett CL Weinberg PD Rozenberg-Ben-Dror K Yarnold PR Kwaan HC Green D . Thrombotic thrombocytopenia purpura associated with ticlopidine: A review of 60 cases. Ann Intern Med 1998;127: 541–4.

Yusuf S Zhao F Mehta SR Chrolavicius S Tognoni G Fox KK . Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345: 494–502.

Mehta SR Yusuf S Peters RJG Bertrand ME Lewis BS Natarajan MK Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001;358: 527–33.

Gaspoz JM Coxson PG Goldman PA Williams LW Kuntz KM Hunink MGM Cost-effectiveness of aspirin, clopidogrel or both for secondary prevention of coronary heart disease. N Engl J Med 2002;346: 1800–6.

Khot UN Nissen SE . Is CURE a cure for acute coronary syndromes? Statistical versus clinical significance. J Am Coll Cardiol 2002;40: 218–9.

Simoons ML . Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularization: The GUSTO IV-ACS randomised trial. Lancet 2001;357: 1915–24.

Boersma E Harrington RA Moliterno DJ White H Theroux P Van de Werf F Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: A meta-analysis of all major randomised clinical trials. Lancet 2002;359: 189–98.

Quinn MJ Plow EF Topol EJ . Platelet glycoprotein IIb/IIIa inhibitors. Recognition of a two-edged sword? Circulation 2002;106: 379–85.

Moliterno DJ Yakubov SJ DiBattiste PM Herrmann HC Stone GW Macaya C Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization with stent placement: The TARGET follow-up study. Lancet 2002;360: 355–60.

Antman EM Cohen M Radley D McCabe C Rush J Premmereur J TIMI 11B (Thrombolysis in Myocardial Infarction) and ESSENCE (Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events) Investigators. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction TIMI 11B-ESSENCE meta-analysis. Circulation 1999;100: 1602–8.

Klein W Buchwald A Hillis SE Monrad S Sanz G Turpie AG Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin In unstable Coronary artery disease study (FRIC). Circulation 1997;96:61–8. Erratum: Circulation 1998;97:413.

Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction. FRAX.I.S. (FRAXiparine in Ischaemic Syndrome). Eur Heart J 1999;20: 1553–62.

Michalis LK Papamichail N Katsouras CS Karahaliou A Sourla E Novas J Enoxaparin versus tinzaparin in the management of unstable coronary artery disease (EVET Study) (abstract). J Am Coll Cardiol 2001;37:365A.

Collet JP Montalescot G Lison L Choussat R Ankri A Drobinski G Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 2001;103: 658–63.

Kereiakes DJ Grines C Fry E Esente P Hoppensteadt D Midei M Enoxaparin and abciximab adjunctive pharmacotherapy during percutaenous coronary intervention. J Invasive Cardiol 2001;13: 272–8.

Ferguson JJ Antman EM Bates ER Cohen M Every NR Harrington RA The use of enoxaparin and IIb/IIIa antagonists in acute coronary syndromes, including PCI: Final results of the NICE-3 study (abstract). J Am Coll Cardiol 2001;37:365A.

Kereiakes DJ Kleiman NS Fry E Mwawasi G Lengerich R Maresh K Dalteparin in combination with abciximab during percutaneous coronary intervention (letter). Am Heart J 2001;141: 348–52.

Cohen M Theroux P Frey MJ White HD Borzak S Weber S Anti-thrombotic combination using tirofiban and enoxaparin: The ACUTE II Study (abstract). Circulation 2000;102(suppl II):II–826.

Blazing MA deLemos JA Dyke CK Califf RM Bilheimer D Braunwald E . The A-to-Z trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. Am Heart J 2001;142: 211–7.

The SYNERGY trial: Study design and rationale. Am Heart J 2002;143: 952–60.

Schwartz GG Olsson AG Ezekowitz MD Ganz P Oliver MF Waters D Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. JAMA 2001;285: 1711–8.